RE: Status Update30 Jan 2026 12:13
In biotech, a partner normally funds the programme, not the company.
They pay for development, regulatory and manufacturing work, not Nuformix’s general PLC running costs.
So a partner can materially reduce burn, but it does not remove all funding needs.
Also worth being clear:
ODD on its own does not automatically mean a partner follows. It helps discussions, but it is not a deal.
Which raises a fair question if cash runway is the main drag on the share price:
Why not fund sooner and remove the overhang, using the same kind of subscription to existing holders (like the 2 for 35 last time)?
Yes, the price may be higher after ODD, but if it is a subscription for existing shareholders, what real difference does timing make, other than clearing uncertainty?